



NCL Method ITA-8.2

Analysis of nanoparticle chemoattractant properties using label-free, real-time chemotaxis assay

Nanotechnology Characterization Laboratory
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.
Frederick, MD 21702
(301) 846-6939
ncl@mail.nih.gov
<http://www.ncl.cancer.gov>



Method written by:

Edward Cedrone¹,

Julia Bui¹

Naichen Yu²,

Marina A. Dobrovolskaia^{1,*}

and is a collaboration between:

1 - Nanotechnology Characterization Lab., Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702; 2 - ACEA Biosciences, Cell Analysis Division, Agilent Technologies, Inc. San Diego, CA 92121

*- address correspondence to: marina@mail.nih.gov

1. Introduction

This document provides a protocol for a real-time, quantitative assessment of the chemoattractant capacity of engineered nanomaterials. Leukocyte recruitment is a central component of the inflammatory process in both host defense against pathogens and a range of inflammatory disorders. Leukocytes respond to pro-inflammatory stimuli, including but not limited to cytokines, chemokines, and prostaglandins, by migrating from the bloodstream to the site of inflammation.

2. Principles

This assay uses the mouse macrophage cell line, RAW 264.7, as a model. The cells are separated from control chemoattractant and test-nanoparticles by an 8 μ m filter. Cell migration through the filter is monitored using a label-free technology developed by ACEA Biosciences/Agilent, wherein cell attachment to gold electrodes on the underside of the filter results in a change of impedance, which subsequently is converted into the cell index which is proportional to the number of cells that migrated through the filter (See appendix 13.1).

3. Reagents, Materials, Cell Lines, and Equipment

Note: The NCL does not endorse any of the suppliers listed below; these reagents were used in the development of the protocol and their inclusion is for informational purposes only. Equivalent supplies from alternate vendors can be substituted. Please note that suppliers may undergo a name change due to a variety of factors. Brands and part numbers typically remain consistent but may also change over time.

3.1 Reagents

- 3.1.1 Phosphate buffered saline (PBS), (GE Life Sciences, SH30256.01)
- 3.1.2 Bovine serum albumin (BSA), (Sigma-Aldrich, A4503)
- 3.1.3 Fetal bovine serum (FBS), (GE Life Sciences, Hyclone, SH30070.03)
- 3.1.4 RPMI-1640, (GE Life Sciences, Hyclone, SH30096.01)
- 3.1.5 Pen/Strep solution, (GE Life Sciences, Hyclone, SV30010)
- 3.1.6 0.25% Trypsin-EDTA, (Invitrogen, 25200-056)

- 3.1.7 AOPI (5 mL), (Nexcelcom, CS2-0106-5ML)
- 3.1.8 L-glutamine, (GE Life Sciences, Hyclone, SH30034.01)
- 3.1.9 Fibronectin, (Sigma-Aldrich, F2006)
- 3.1.10 fMLP, (Sigma-Aldrich, F3506)
- 3.1.11 β -mercaptoethanol (Sigma-Aldrich, M3148)
- 3.2 Materials
 - 3.2.1 Pipettes covering the range of 0.05 to 10 mL
 - 3.2.2 RTCA CIM-Plate 16 (ACEA/Agilent, 05665825001)
 - 3.2.3 Polypropylene tubes, 50 and 15 mL
 - 3.2.4 Multichannel pipettor
 - 3.2.4 Counting Chamber (Nexcelcom, CHT4-SD100-014)
- 3.3 Cell Line
 - 3.3.1 RAW 264.7 (mouse macrophage cells), (ATCC, ATCC[®]-TIB-71[™])
- 3.4 Equipment
 - 3.4.1 Centrifuge capable of operating at 400 x g
 - 3.4.2 Refrigerator, 2-8°C
 - 3.4.3 Freezer, -20°C
 - 3.4.4 Cell culture incubator with 5% CO₂ and 95% humidity.
 - 3.4.5 Biohazard safety cabinet approved for level II handling of biological material
 - 3.4.6 Inverted microscope
 - 3.4.7 Vortex
 - 3.4.8 Cellometer Auto 2000 Cell Counter, (Nexcelcom)
 - 3.4.9 xCELLigence[®] RTCA DP Instrument, (ACEA/Agilent, 00380601050)

4. Reagent and Control Preparation

4.1 Complete RPMI-1640 medium

The complete RPMI medium should contain the following reagents:

10% FBS (heat inactivated)

4 mM L-glutamine

100 U/mL penicillin

100 µg/mL streptomycin sulfate

50 µM β-mercaptoethanol

Store at 2-8°C protected from light for no longer than 1 month. Before use, warm in a water bath.

4.2 Starvation Media (SM)

The starvation RPMI medium should contain the following reagents:

0.2 % BSA

4 mM L-glutamine

100U/mL penicillin

100 µg/mL streptomycin sulfate

50 µM β-mercaptoethanol

Store at 2-8°C protected from light for no longer than 1 month. Before use, warm the medium in a water bath.

4.3 Heat-inactivated fetal bovine serum

Thaw a bottle of FBS at room temperature, or overnight at 2-8°C and allow to equilibrate to room temperature. Incubate 30 minutes at 56°C in a water bath mixing every 5 minutes. Single-use aliquots may be stored at 2-8°C for up to one month or at a nominal temperature of -20°C indefinitely.

4.4 Fibronectin

Reconstitute to 1 mg/mL in cell culture water, then incubate at 37°C for 30 minutes, aliquot 25 µL/vial and store at -20°C. Use 5 µg/mL final concentration for plate coating.

4.5 Negative Control

Use starvation medium as a negative control. Process this control the same way as the study samples.

4.6 Positive Control, fMLP (Sigma, F3506)

Reconstitute at 4 mg/mL with DMSO, aliquot 50 µL/vial and store at -20°C. Use 1 ng/mL final concentration.

4.8 Vehicle Control

Vehicle control is the buffer or media used to formulate test nanomaterials.

Common excipients used in nanoformulations are trehalose, sucrose, and albumin.

However, other reagents and materials are also used alone or in combination. Vehicle control should match formulation buffer of the test-nanomaterial by both composition and concentration. This control can be skipped if nanoparticles are stored in PBS.

5. Preparation of Study Samples

This assay requires 2.0 mL of nanoparticles, at 1x the highest final tested concentration dissolved/resuspended in starvation medium. The concentration is selected based on the plasma concentration of the nanoparticle at the intended therapeutic dose. For the purpose of this protocol this concentration is called “theoretical plasma concentration”. Considerations for estimating theoretical plasma concentration were reviewed elsewhere (1) and are summarized in Box 1 below.

Box 1. Example Calculation of Nanoparticle concentration for In Vitro Test

In this example, we assume the mouse dose is known to be 123 mg/kg.

$$\text{human dose} = \frac{\text{mouse dose}}{12.3} = \frac{123 \frac{\text{mg}}{\text{kg}}}{12.3} = 10 \text{ mg/kg}$$

Blood volume constitutes approximately 8% of body weight, (e.g. a 70 kg human has approximately 5.6 L (8% of 70) of blood). This allows us to get a very rough estimation of what the maximum blood concentration may be.

$$\begin{aligned} \text{in vitro concentration}_{\text{human maxtrix}} &= \frac{\text{human dose}}{\text{human blood volume}} = \frac{70 \text{ kg} \times 10 \frac{\text{mg}}{\text{kg}}}{5.6 \text{ L}} \\ &= \frac{700 \text{ mg}}{5.6 \text{ L}} = 0.125 \text{ mg/mL} \end{aligned}$$

The assay will evaluate 4 concentrations: 10 X (or when feasible 100X, 30X or 5X) of the theoretical plasma concentration, theoretical plasma concentration and two 1:5 serial dilutions of the theoretical plasma concentration. When the intended therapeutic concentration is unknown, the highest final concentration is 1 mg/mL or the highest reasonably achievable concentration. For example, if the final theoretical plasma concentration to be tested is 0.2 mg/mL, then a stock of 2 mg/mL will be prepared and diluted 10-fold (0.2 mg/mL), followed by two 1:5 serial

dilutions (0.04 and 0.008 mg/mL). Use 160 μ L of each of these samples per well. Each nanoparticle concentration is plated 3 times.

6. RAW 264.7 Cell Preparation

RAW 264.7 is a mouse macrophage cell line. Cultures can be maintained by subculture at a ratio of 1:3 to 1:6. Do not allow cells to become confluent. Cell morphology should have a flat, dendritic-like appearance, if grown under optimal conditions (Figure 1).




Figure 1. Morphology of RAW264.7 cells. (A) Morphology of cells suitable for the chemotaxis assay (B) Morphology of cells which should not be used for the chemotaxis assay.

- 6.1 Expand cells until they are approximately 60-70% confluent. The day before the experiment, change the medium from normal growth medium to starvation medium and incubate overnight (16 - 18h).
- 6.2 On the day of the experiment, count cells using AOPI and adjust concentration to 1×10^6 **viable** cells/mL in Starvation Medium.

7. Fibronectin Coating

See images in the Appendix I3.4

- 7.1 Dilute 25 μ L of stock (1 mg/mL) fibronectin in 1X PBS to a final volume of 5 mL.
- 7.2 Add 30 μ L to the electrode on the underside of each well; be careful not to pierce the electrode.

- 7.3 Incubate at room temperature for 30 minutes, aspirate and allow to air dry for 30 minutes.
- 7.4 Repeat steps 7.2 and 7.3 with the upper side of the wells.
- 7.5 Coated plates may be stored under sterile conditions for up to 2 weeks at 4°C.

8. Experimental Procedure

The procedure described below is based on reference 2.

- 8.1 Add 160 µL of the test reagents to their respective wells in the bottom chamber of the CIM-Plate 16 (a meniscus should be formed at the top of each well, see figures in Appendix 13.3).
- 8.2 Attach the upper chamber of the CIM-Plate 16 carefully to avoid creating bubbles.
- 8.3 Add 25 µL of starvation medium to all 16 wells of the top chamber.
- 8.4 Place the chamber(s) into the RTCA DP instrument according to the experimental plan and allow medium/test reagents to equilibrate for 60 minutes.
- 8.5 Perform a background read.
- 8.6 Remove the plate from the instrument and add 100 µL of cell suspension to the top wells (1×10^5 cells/well).
- 8.7 Allow the cells to settle in the wells at RT for 30 minutes before replacing on the instrument.
- 8.8 Place chamber in the instrument and start the protocol (see instrument settings in Appendix 13.6).
- 8.9 Acquire data for 72 hours.

9. Calculations

- 9.1 Calculate area under the curve (AUC) for the control and test samples using the instrument software or Excel, then compare the AUC of the test samples to that of the control sample. Use statistical analysis to evaluate the significance of the observed difference.

10. Acceptance Criteria

10.1 %CV for each control and test sample should be less than 30%.

11. References

1. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013 Dec 10;172(2):456-66
2. xCELLigence® Real-Time Cell Analysis (CIM Protocol). Using the xCELLigence® RTCA DP Instrument to perform Cell Invasion and Migration (CIM) Assays, ACEA Biosciences 2015


12. Abbreviations

BSA	bovine serum albumin
CIM	cell invasion/migration
CV	coefficient of variation
FBS	fetal bovine serum
PBS	phosphate buffered saline
RPMI	Roswell Park Memorial Institute
RTCA	Real-Time Cell Analysis
SD	standard deviation
SM	starvation media
VC	vehicle control

13. Appendix

Images shown in sections 13.1-13.4 are reproduced from reference 2 with permission.

13.1 CIM-Plate 16 Schematic



13.2 ACEA CIM Plate 16 images





Fig A: ACEA CIM-Plate 16, unassembled.


Fig B: ACEA CIM-Plate 16, assembled.

13.3 Reagent loading image



Sample loading procedure.
Plate bottom.

13.4 Fibronectin-coating Images



13.5 Example of Assay Plate Map

	PLATE 1		Plate 2		Plate 3	
	1A	1B	2A	2B	3A	3B
1	Untreated	Untreated	Untreated	Untreated	Untreated	Untreated
2	PC	PC	PC	PC	PC	PC
3	Test 1	Test 1	Test 1	Test 1	Test 1	Test 1
4	Test 2	Test 2	Test 2	Test 2	Test 2	Test 2
5	Test 3	Test 3	Test 3	Test 3	Test 3	Test 3
6	Test 4	Test 4	Test 4	Test 4	Test 4	Test 4
7	Medium + Test 1	Medium + Test 1	Medium + Test 1	Medium + Test 1	Medium + Test 1	Medium + Test 1
8	Medium Only	Medium Only	Medium Only	Medium Only	Medium Only	Medium Only

13.6 Instrument settings

Step #	Step Name	Interval	
		(min)	Sweeps
1	Background	1.00	1
2	Cell Seed	1.00	1
3	Cell Attach	0.50	500
4	Cell Chemotaxis	15.0	300